Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome

Tandon, Rajiv; DeQuardo, John R.; Taylor, Stephan F.; McGrath, Marlene; Jibson, Michael D.; Eiser, Alan S.; Goldman, Mona

doi:10.1016/s0920-9964(99)00163-2

Cited by 74 publications

(44 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the concept of PNS has been present in the literature for several years [105][106][107], only recently this approach has received more attention. Different terminology and criteria have been used to describe and identify PNS, yielding mixed results in terms of structural, neuropsychological and functional correlates of PNS [108].…”

Section: Persistent Negative Symptomsmentioning

confidence: 99%

Neurobiological background of negative symptoms

Galderisi

Merlotti

Mucci

2015

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Studies investigating neurobiological bases of negative symptoms of schizophrenia failed to provide consistent findings, possibly due to the heterogeneity of this psychopathological construct. We tried to review the findings published to date investigating neurobiological abnormalities after reducing the heterogeneity of the negative symptoms construct. The literature in electronic databases as well as citations and major articles are reviewed with respect to the phenomenology, pathology, genetics and neurobiology of schizophrenia. We searched PubMed with the keywords "negative symptoms," "deficit schizophrenia," "persistent negative symptoms," "neurotransmissions," "neuroimaging" and "genetic." Additional articles were identified by manually checking the reference lists of the relevant publications. Publications in English were considered, and unpublished studies, conference abstracts and poster presentations were not included. Structural and functional imaging studies addressed the issue of neurobiological background of negative symptoms from several perspectives (considering them as a unitary construct, focusing on primary and/or persistent negative symptoms and, more recently, clustering them into factors), but produced discrepant findings. The examined studies provided evidence suggesting that even primary and persistent negative symptoms include different psychopathological constructs, probably reflecting the dysfunction of different neurobiological substrates. Furthermore, they suggest that complex alterations in multiple neurotransmitter systems and genetic variants might influence the expression of negative symptoms in schizophrenia. On the whole, the reviewed findings, representing the distillation of a large body of disparate data, suggest that further deconstruction of negative symptomatology into more elementary components is needed to gain insight into underlying neurobiological mechanisms.

show abstract

Section: Persistent Negative Symptomsmentioning

confidence: 99%

Neurobiological background of negative symptoms

Galderisi

Merlotti

Mucci

2015

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…This fi nding supports the assumption that developing negative symptoms and social dysfunction may be an inherent part of the progressing psychotic disorder and that in PLA 2 changes might belong to the core illness process. A new and interesting aspect is the observation of the in PLA 2 linked responsiveness of negative symptoms, as acute-phase negative symptoms were found much better responsive to antipsychotic treatment than enduring negative symptoms (Tandon et al 2000). Thus, in PLA 2 hyperactivity that is associated with dynamic negative symptoms at the time of initial acute manifestation might be prognostically meaningful.…”

Section: Discussionmentioning

confidence: 99%

Phospholipase A₂activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12

Smesny

Kunstmann

et al. 2010

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…Areas of investigation should also include the secondary long-term effects of elevated circulating cortisol, e.g. hypertension, increased abdominal fat, decreased bone density, and cognitive impairment [5], negative symptomatology [10,11], and brain morphology [13]. …”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, plasma concentrations of ACTH and cortisol correlate positively with negative symptomatology in schizophrenic patients [10,11] and negatively with cognitive performance in a larger group of patients and controls [12]. Additionally, persistent hypercortisolaemia in schizophrenia is associated with poor outcome and ventricular enlargement [13].…”

Section: Introductionmentioning

confidence: 97%

Ziprasidone decreases cortisol excretion in healthy subjects

Meier

Neumann

Jordan

et al. 2005

Brit J Clinical Pharma

View full text Add to dashboard Cite

Br J Clin Pharmacol AimsTo determine the influence of the atypical antipsychotic ziprasidone on cortisol excretion. MethodsIn a double-blind, placebo-controlled, randomized cross-over design 11 healthy male subjects were studied twice for 2 consecutive nights (N1, undisturbed sleep conditions; N2, exposure to acoustic stress) 5 days apart. Placebo or ziprasidone 40 mg was administered orally 2 h before bedtime on N1 and N2. Urine was collected during three fractionated collection periods (evening; night; morning) for the later determination of cortisol concentrations by standard radioimmunoassays. ResultsZiprasidone decreased the total amount of cortisol excreted by 4.9 (95% CI 3.3, 6.5) m g during N1 and by 10.8 (95% CI 5.7, 15.8) m g during N2 ( P < 0.002) . This effect was still detectable in the morning ( P < 0.02), with decreases of 5.8 (95% CI -2.8, 14.4) m g after N1 and by 12.1 (95% CI 2.8, 21.4) m g after N2 .The effect subsided in the evening. A significant intervention-condition interaction ( P < 0.02), was found. The significant increase in cortisol excretion during acoustic stress observed with placebo was absent after treatment with ziprasidone. ConclusionsThe significant decrease in nocturnal cortisol excretion following ziprasidone reflects a decreased activity of the HPA-axis in healthy subjects. This effect may be an important contributor to the mode of action of ziprasidone in different patient populations, particularly in the treatment of depression and in cognitive impairment in schizophrenia.

show abstract

Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome

Cited by 74 publications

References 58 publications

Neurobiological background of negative symptoms

Neurobiological background of negative symptoms

Phospholipase A₂activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12

Ziprasidone decreases cortisol excretion in healthy subjects

Contact Info

Product

Resources

About

Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome

Cited by 74 publications

References 58 publications

Neurobiological background of negative symptoms

Neurobiological background of negative symptoms

Phospholipase A2activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12

Ziprasidone decreases cortisol excretion in healthy subjects

Contact Info

Product

Resources

About

Phospholipase A₂activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12